MPR2d
Fabhalta Approved as First Treatment for C3 Glomerulopathy
The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.
Pharmabiz5d
US FDA approves Novartis’ oral Fabhalta for treatment of adults with C3 glomerulopathy
US FDA approves Novartis’ oral Fabhalta for treatment of adults with C3 glomerulopathy: Basel Saturday, March 22, 2025, 09:00 Hrs [IST] Novartis announced that oral Fabhalta (ip ...
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
On Thursday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE:NVS) oral Fabhalta (iptacopan) for ...
Fierce Pharma6d
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
The American Journal of Managed Care6d
FDA Approves Oral Iptacopan for C3 Glomerulopathy
The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults with C3 glomerulopathy (C3G), according ...
Le Lézard6d
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
Omeros Corporation today reported that clinical trial site activation for enrollment is underway for the company's Phase 3 program evaluating zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH).
pharmaphorum6d
Fabhalta is first FDA-approved therapy for rare disease C3G
Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting ...
Medindia6d
Novartis receives third FDA approval for oral Fabhalta (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis Media Relations E-mail: [email protected] Novartis Investor Relations Central investor relations line: +41 61 ...
DelveInsight Business Research, LLP: EMPAVELI's Market Success Underscores Growing Demand for Complement Inhibitor Therapies | DelveInsight
EMPAVELI's unique mechanism of targeting C3 broadens its applicability beyond PNH, including other complement-driven diseases like geographic atrophy and immune complex-mediated diseases. With ...
ALZFORUM13d
After Immunotherapy, Amyloid Clearance Comes Down to Microglial Moods
Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to ...